Bridgewater, NJ, September, 8, 2008: Ortho Biotech Products, L.P. today announced that the Company has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the combination of DOXIL (doxorubicin HCl liposome injection) and Taxotere (docetaxel)  for the treatment of women with advanced breast cancer who have received prior anthracycline treatment.

Rome, Italy, September 8, 2008: Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA (saxagliptin), an investigational selective inhibitor with extended binding to the dipeptidyl peptidase-4 (DPP-4) enzyme in development by Bristol-Myers Squibb Company [NYSE:BMY] and AstraZeneca [NYSE:AZN], produced significant reductions across all key measures of glucose control studied [glycosylated hemoglobin level (A1C), fasting plasma glucose (FPG) and postprandial glucose (PPG)] when added to a sulfonylurea (SU) or a thiazolidinedione (TZD) in people with inadequately controlled type 2 diabetes, compared to placebo added to either an increased dose of SU or a stable dose of TZD. The addition of saxagliptin to SU or TZD was well tolerated over the course of the studies, and significantly more people were able to achieve target A1C of less than 7 percent versus the comparators.